This
hypothesis can be ignored only at the initial recognition of a biological asset, for which there
are not available prices or values determined on the market and for which the alternative
estimations of the fair value are not clearly reliable. In these cases, the biological assets will
be evaluated at cost less any cumulated depreciation and any loss from cumulated
depreciation.